Prepared for
MedTech
Hero Finding
Six in ten surgeons describe themselves as fast followers, and the unaware cohort projects a higher steady-state share than the aware cohort once the evidence reaches them.
Across both aware and unaware non-user surgeons, roughly six in ten identified as fast followers waiting for initial clinical experience or peer validation. Early adopters were rare. Unaware surgeons projected a meaningfully higher conservative steady-state share than aware surgeons, suggesting the awareness cohort is calibrated by exposure to early launch friction while the unaware cohort projects from category fit alone.
63%
Unaware cohort identifying as fast followers
43%
Conservative steady-state share · unaware cohort
45%
Reach steady-state within 6 to 12 months · unaware
Study Design
N=185 orthopedic surgeons · current users, aware non-users, unaware non-users, previously-used · mixed-method survey.
The sample was structured to read both current adoption behavior and forward-looking intent across the awareness funnel. Skip logic ensured that adoption-curve questions were served only to surgeons indicating any non-zero likelihood of adoption, with mid-fielding logic adjustment to include the neutral-likelihood respondents.
Sample segmentation
Unaware non-users · 104
Aware non-users · 64
Previously used · 12
Current users · 5
Interview guide · core topics
- Current RCR volume share running on the novel technology among existing users
- Usage evolution since first patient case: rapid increase, gradual increase, stabilized, or limited expansion
- Adoption likelihood across a 1 to 7 scale among aware and unaware non-users
- Expected adoption approach: early adopter, fast follower, conservative user, or unsure
- First 12-month volume transition: conservative and optimistic share-of-volume estimates
- Steady-state RCR volume share once adoption stabilizes
- Time horizon to reach steady-state usage from initial adoption decision
- Drivers of usage expansion and barriers to broader patient eligibility
Recruit criteria
- Practicing orthopedic surgeons performing rotator cuff repair as a routine procedure
- Current users, aware non-users, unaware non-users, and previously-used surgeons across the awareness funnel
- Mix of generalist and specialist surgeons across major metro, mid-size metro, and community practice settings
- Decision-making authority on technology selection or significant influence on case-level technique choice
Key Findings
What the adoption research surfaced for the launch model.
Six signals defined the share-of-volume forecast, the surgeon-segment prioritization, and the evidence investment plan for the conservative cohort.
63%
Unaware surgeons identifying as fast followers
43%
Conservative steady-state share · unaware cohort
73%
Optimistic steady-state share · unaware cohort
45%
Reach steady-state in 6 to 12 months · unaware
33%
Steady-state share expected by current users still expanding
01
Fast followers dominate the addressable cohort: a majority across both aware and unaware non-users.
The market is not led by early adopters. Only a small share of both aware and unaware surgeons identify as early adopters willing to trial without prior clinical experience. The dominant approach is the fast follower (majority in both cohorts) waiting on initial clinical experience or peer validation. The launch motion needs to manufacture that peer validation signal at scale, not chase the small early-adopter pool.
02
The unaware cohort projects higher steady-state share than the aware cohort: a calibration gap of 10 percentage points.
Conservative steady-state share lands meaningfully higher for unaware surgeons than for aware. Optimistic share shows a similar advantage for the unaware cohort. The gap is consistent across both estimates and likely reflects the aware cohort discounting for early launch friction (fixation-construct concerns, surgical-skill match to published outcomes) that has not yet reached the unaware cohort. At this stage of launch, awareness without resolved evidence drags share rather than lifting it.
03
Time-to-stable concentrates in the 6 to 12 month band: a plurality of the unaware cohort reaches steady state in that window.
Across both cohorts, a strong majority of surgeons project reaching steady-state usage within 12 months of adoption, with the unaware cohort reaching stable adoption faster. The 6 to 12 month band is the modal expectation. Forecast and field-force capacity models should plan for that ramp shape: rapid initial trial, then stabilization within a year, with limited tail beyond 18 months.
04
Current users sit at a modest RCR volume share today, with a meaningfully higher share expected at steady state among those still expanding.
Current users (n=5) report a modest share of RCR cases on the novel technology today, with a wide range across the cohort. Among those who described usage as still expanding, the expected steady-state share was materially higher. That trajectory anchors the realistic share band for the early commercial cohort and frames the upper end of the conservative scenario for the broader market.
05
Conservative cohort behavior is shaped by construct and validation concerns: roughly a quarter to a third of the addressable cohort requires substantial long-term evidence.
A meaningful minority of both unaware and aware surgeons identify as conservative users requiring substantial long-term evidence and broad adoption before they will trial. Verbatim concerns center on fixation-construct performance and equivalence to published trial outcomes. The conservative cohort is reachable but requires a different evidence package: long-term outcomes data, technique training matched to published protocols, and broad clinical experience from peers.
06
First-year volume transition projections sit well below steady-state: a 13 to 30 percentage-point ramp.
Conservative first-year transition lands materially below steady-state for both cohorts. Optimistic first-year is also below steady-state across both estimates. The ramp is real and consistent. Early-year revenue forecasts that assume immediate steady-state share will overshoot; the launch model needs the first-year discount built in.
“Once I felt comfortable with it, I started incorporating it into more cases. It became less of an experimental issue and more of being able to use it in patients that warranted it.”— Current user, orthopedic surgeon, generalist, major metropolitan area
Crosstab · Adoption Curve by Awareness
Adoption approach, share of volume, and time-to-stable by awareness cohort.
The unaware cohort projects higher fast-follower share, higher conservative and optimistic steady-state share, and faster time-to-stable than the aware cohort. The awareness gap is a calibration gap, not a fit gap.
| Aware non-users (n=43-61) | Unaware non-users (n=89-101) | |
|---|---|---|
| Early adopter share | 5% | 9% |
| Fast follower share | 60% | 63% |
| Conservative user share | 30% | 25% |
| Conservative first-year volume | 26% | 30% |
| Optimistic first-year volume | 50% | 64% |
| Conservative steady-state share | 33% | 43% |
| Optimistic steady-state share | 61% | 73% |
| Reach steady state within 12 months | 56% | 64% |
N=185 orthopedic surgeons across awareness funnelSteady-state share gap: +10pp unaware over aware (conservative)Fast-follower share gap: +3pp unaware over aware
Voice of Customer
How orthopedic surgeons describe the trial-to-stable journey.
Verbatim excerpts from current users and the conservative cohort, selected to represent the adoption pattern, the validation bar, and the patient-eligibility expansion logic.
Current User · Trial to Stable
“Once I felt comfortable with it, I started incorporating it into more cases. It became less of an experimental issue and more of being able to use it in patients that warranted it.”
— Current user, orthopedic surgeon, generalist, major metropolitan area
Current User · Patient Eligibility Expansion
“Like any new technology, you initially use it on cases where it is the perfect match. For me, that is older patients with poor tissue. I may start using it for more traditional tears and younger patients. I am not sure what the limit will be, but I have been happy so far.”
— Current user, orthopedic surgeon, generalist, mid-size metro area
Conservative · Validation Standard
“Older surgeon, kind of stuck in my ways. This is an area that definitely needs help, a major problem are retears. I am still concerned about the fixation side overall. I just want to be sure my surgical skills meet what the published trial outcomes show. You have to equal what is being published.”
— Current user, orthopedic surgeon, specialist, major metropolitan area
Current User · Outcome Confidence
“I am starting to see really good responses to the procedure.”
— Current user, orthopedic surgeon, generalist, major metropolitan area
Adoption Approach · Fast Follower Logic
“We will wait for initial clinical experience or peer validation before we trial it. That is the standard approach for any new repair technology in this space.”
— Aware non-user, orthopedic surgeon, fast-follower segment
Counter-intuitive
Awareness without resolved evidence drags projected share rather than lifting it.
The intuitive expectation is that surgeon awareness lifts adoption likelihood and steady-state share. The data shows the opposite at this stage of launch. The unaware cohort projected higher conservative steady-state share, higher optimistic share, and faster time-to-stable than the aware cohort. The aware cohort has been exposed to early launch friction (fixation-construct concerns, technique-match requirements, evidence ambiguity) without yet seeing those concerns resolved by broad clinical experience. Until the evidence base catches up to the awareness front, awareness functions as a discount on share rather than a premium.
Strategic Implications
Three commercial moves from the adoption research.
What the commercial team carried into the launch model and the field-force capacity plan, grounded in the fast-follower share, the time-to-stable distribution, and the awareness-cohort calibration gap.
01
Build the launch motion around manufacturing fast-follower validation at scale.
A majority of the addressable cohort is waiting for initial clinical experience or peer validation. The launch motion should prioritize structured peer-to-peer programs, early-experience case publication, and visible reference surgeon momentum over generalized awareness campaigns. The early-adopter pool is too small to drive volume on its own.
02
Plan the launch model with first-year volume materially below steady-state and plan for the ramp over 6 to 12 months.
First-year transition projections sit materially below steady-state in the conservative scenario across both cohorts. Forecast and field-force capacity models should build the ramp into the first 12 months, anchor steady-state share at the conservative range established in the research, and reserve the optimistic upside scenario for when validation evidence resolves.
03
Resolve the awareness-cohort calibration gap with construct and outcomes evidence.
The aware cohort is projecting lower share than the unaware cohort because early launch friction has not yet been resolved. The evidence priorities are fixation-construct performance data, technique-match outcomes versus published protocols, and long-term retear rates. Closing that calibration gap should lift aware-cohort steady-state projections toward the unaware-cohort baseline in the conservative scenario.
Success criteria · 12 months
- Reference surgeon program established with documented peer validation pathway
- First-year volume tracking against the 26 to 30% conservative band
- Anchor and outcomes evidence package published and distributed to the aware cohort
- Time-to-stable tracked against the 6 to 12 month modal expectation
Risk register
| Conservative cohort evidence requirements unmet | HIGH |
| Fixation-construct performance concerns persist in the field | HIGH |
| First-year overshoot in launch revenue forecast | MED |
| Fast-follower validation signal does not scale | MED |
| Patient-eligibility expansion stalls beyond initial fit | LOW |